Medically reviewed by Renita White, MD Perimenopause is the transition period when the female body starts to shift from ...

Click here to get the full newsletter in your inbox, including answers to reader questions and a summary of new scientific ...

Veozah is an oral, neurokinin 3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. The labeling for the product now includes a boxed warning ...

Benedict, Ph.D., Christina Borgeest, B.A., Jodi A. Flaws, Ph.D. The reasons for the discrepancies among studies on estrogen and hot flashes are unknown. It is possible they stem from differences ...

Maura K. Whiteman, Ph.D., Catherine A. Staropoli, M.D., Jamie C. Benedict, Ph.D., Christina Borgeest, B.A., Jodi A. Flaws, Ph.D.

Low doses of antidepressant medications may help reduce symptoms of menopause, including hot flashes. Though these generally are not as effective as hormone replacement therapy, they are an option for ...

The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah, a medication used to relieve hot flashes ... of Veozah treatment and follow ...

Veozah is an oral, neurokinin 3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. The labeling for the product now includes a boxed warning ...

Strictly Come Dancing may have come to an end over the weekend with Chris McCausland and Dianne Buswell taking home the Glitterball Trophy. But fans won't have too long to wait until the next ...

Depression treatments can include psychotherapy ... As with any medication, antidepressants may cause side effects. A person should discuss the benefits and risks with their doctor before taking ...

A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. Shares of Indoco Remedies on Tuesday ended 1 per cent up at Rs 344 apiece ...

Nvidia stock may be under pressure in the short-term. It slipped below its short-term moving averages, testing for support levels near the 200-day MA. Cramer cautioned investors predicting a ...